Drug Trial Radar · NCT02536755
Phase 3b Study to Evaluate Skeletal Response to Eliglustat in Adult Patients Who Completed Phase 2 or Phase 3 Studies
Last checked: Nov 19, 2026Latest source record: Jul 15, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
31
Actual
Start
Oct 27, 2015
Primary completion
Jun 24, 2021
Study completion Jun 24, 2021
Sponsor
- Lead sponsor
- Genzyme, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Sep 1, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: Evaluate long term skeletal response to eliglustat in adult participants who successfully completed one of the Phase 2 or Phase 3 eliglustat studies. Secondary Objective: Evaluate the safety of eliglustat (by serious adverse event continuous monitoring), the quality of life (Short Form-36 Health Survey \[SF-36\]) and biomarkers of Gaucher disease type 1 (GD1) (chitotriosidase, plasma glucosylceramide \[GL-1\] and lyso glucosylceramide \[lyso-GL-1\]) in adult participants who successfully completed one of the Phase 2 or Phase 3 studies.
Conditions
- Gaucher Disease
Interventions
Eliglustat, GZ385660Drug
Pharmaceutical form: capsule Route of administration: oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Mobility Status Assessments at Study Baseline, Weeks 52, 104, 156 and 208Time frame: Study Baseline, Weeks 52, 104, 156 and 208
- Number of Participants With Bone Pain Levels During the Past 4 Weeks at Study Baseline, Weeks 52, 104, 156 and 208Time frame: Study Baseline, Weeks 52, 104, 156 and 208
- Number of Participants With Bone Crisis at Study Baseline, Weeks 52, 104, 156 and 208Time frame: Study Baseline, Weeks 52, 104, 156 and 208
- Change From Current Study Baseline in Total Bone Marrow Burden (BMB) Scores at Weeks 52, 104, 156 and 208Time frame: Study Baseline, Weeks 52, 104, 156 and 208
- Change From Eliglustat Baseline in Total Bone Marrow Burden (BMB) Scores at Weeks 52, 104, 156 and 208Time frame: Eliglustat Baseline, Weeks 52, 104, 156 and 208 of the current study
- Change From Current Study Baseline in Total Spine and Femur Bone Mineral Density (BMD) at Weeks 52, 104, 156 and 208Time frame: Study Baseline, Weeks 52, 104, 156 and 208
- Change From Eliglustat Baseline in Total Spine and Femur Bone Mineral Density (BMD) at Weeks 52, 104, 156 and 208Time frame: Eliglustat Baseline, Weeks 52, 104, 156 and 208 of the current study
- Change From Current Study Baseline in Spine and Femur Total T-Scores for BMD at Weeks 52, 104, 156 and 208Time frame: Study Baseline, Weeks 52, 104, 156 and 208
- Change From Eliglustat Baseline in Spine and Femur Total T-Scores for BMD at Weeks 52, 104, 156 and 208Time frame: Eliglustat Baseline, Weeks 52, 104, 156 and 208 of the current study
- Change From Current Study Baseline in Spine and Femur Total Z-Scores for BMD at Weeks 52, 104, 156 and 208Time frame: Study Baseline, Weeks 52, 104, 156 and 208
- Change From Eliglustat Baseline in Spine and Femur Total Z-Scores for BMD at Weeks 52, 104, 156 and 208Time frame: Eliglustat Baseline, Weeks 52, 104, 156 and 208 of the current study
- Total Number of New or Worsening Osteonecrosis Events for Spine and Femur at Study Baseline, Week 52, 104, 156 and 208Time frame: Study Baseline, Weeks 52, 104, 156 and 208
- Total Number of New or Worsening Fracture Events for Spine and Femur at Study Baseline, Week 52, 104, 156 and 208Time frame: Study Baseline, Weeks 52, 104, 156 and 208
- Total Number of New or Worsening Infarcts Events for Spine and Femur at Study Baseline, Week 52, 104, 156 and 208Time frame: Study Baseline, Weeks 52, 104, 156 and 208
- Total Number of New or Worsening Lytic Lesions Events for Spine at Study Baseline, Week 104, and 208Time frame: Study Baseline, Weeks 104, and 208
- Observed Annual Incidence Rate for Spine and Femur Osteonecrosis at Week 52, 104, 156 and 208Time frame: For 52 Weeks (i.e., 1 year),104 Weeks (i.e., 2 year), 156 Weeks (i.e., 3 year) and 208 Weeks (i.e., 4 years)
- Observed Annual Incidence Rate for Spine and Femur Fracture at Week 52, 104, 156 and 208Time frame: For 52 Weeks (i.e., 1 year),104 Weeks (i.e., 2 year), 156 Weeks (i.e., 3 year) and 208 Weeks (i.e., 4 years)
- Observed Annual Incidence Rate for Spine and Femur Infarcts at Week 52, 104, 156 and 208Time frame: For 52 Weeks (i.e., 1 year),104 Weeks (i.e., 2 year), 156 Weeks (i.e., 3 year) and 208 Weeks (i.e., 4 years)
- Observed Annual Incidence Rate for Spine Lytic Lesion at Week 104, and 208Time frame: For 104 Weeks (i.e., 2 year), and 208 Weeks (i.e., 4 years)
- Change From Current Study Baseline in Bone Biomarker Level: Macrophage Inflammatory Protein 1 Beta (MIP-1β) at Weeks 26, 52, 78, 104, 130, 156,182, 208 and 234Time frame: Study Baseline, Weeks 26, 52, 78, 104, 130, 156, 182, 208 and 234
- Change From Eliglustat Baseline in Bone Biomarker Level: Macrophage Inflammatory Protein 1 Beta (MIP-1β) at Weeks 26, 52, 78, 104, 130, 156,182, 208 and 234Time frame: Eliglustat Baseline, Weeks 26, 52, 78, 104, 130, 156,182, 208 and 234 of the current study
- Change From Current Study Baseline in Bone Biomarker Level: Procollagen 1 N- Terminal Propeptide (P1NP) at Weeks 26, 52, 78, 104, 130, 156,182, 208 and 234Time frame: Study Baseline, Weeks 26, 52, 78, 104, 130, 156,182, 208 and 234
- Change From Eliglustat Baseline in Bone Biomarker Level: Procollagen 1 N- Terminal Propeptide (P1NP) at Weeks 26, 52, 78, 104, 130, 156,182, 208 and 234Time frame: Eliglustat Baseline, Weeks 26, 52, 78, 104, 130, 156,182, 208 and 234 of the current study
- Change From Current Study Baseline in Bone Biomarker Level: Type 1 Collagen C-Telopeptides (CTx) at Weeks 26, 52, 78, 104, 130, 156,182, 208 and 234Time frame: Study Baseline, Weeks 26, 52, 78, 104, 130, 156,182, 208 and 234
- Change From Eliglustat Baseline in Bone Biomarker Level: Type 1 Collagen C-Telopeptides (CTx) at Weeks 26, 52, 78, 104, 130, 156,182, 208 and 234Time frame: Eliglustat Baseline, Weeks 26, 52, 78, 104, 130, 156,182, 208 and 234 of the current study
Locations
4 sites in 3 countries. Site status is shown where the registry gives one.
Investigational Site Number 124002
Montreal, Canada
Investigational Site Number 643001
Moscow, Russia
Investigational Site Number 643002
Saint Petersburg, Russia
Investigational Site Number 788001
Tunis, Tunisia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.